DCF Advisers LLC Acquires New Position in LENSAR, Inc. $LNSR

DCF Advisers LLC acquired a new stake in LENSAR, Inc. (NASDAQ:LNSR) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 118,217 shares of the company’s stock, valued at approximately $675,000.

A number of other hedge funds also recently bought and sold shares of LNSR. Credit Industriel ET Commercial lifted its stake in LENSAR by 0.8% in the 4th quarter. Credit Industriel ET Commercial now owns 124,483 shares of the company’s stock worth $1,448,000 after purchasing an additional 1,000 shares in the last quarter. BNP Paribas Financial Markets grew its position in shares of LENSAR by 129.0% in the third quarter. BNP Paribas Financial Markets now owns 2,008 shares of the company’s stock valued at $25,000 after purchasing an additional 1,131 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in shares of LENSAR by 26.8% in the third quarter. JPMorgan Chase & Co. now owns 5,928 shares of the company’s stock valued at $73,000 after purchasing an additional 1,254 shares during the last quarter. Barclays PLC increased its holdings in shares of LENSAR by 10.3% in the fourth quarter. Barclays PLC now owns 14,857 shares of the company’s stock valued at $173,000 after purchasing an additional 1,389 shares during the last quarter. Finally, Vanguard Group Inc. increased its holdings in shares of LENSAR by 0.3% in the third quarter. Vanguard Group Inc. now owns 507,603 shares of the company’s stock valued at $6,269,000 after purchasing an additional 1,446 shares during the last quarter. Institutional investors and hedge funds own 40.15% of the company’s stock.

Analyst Upgrades and Downgrades

LNSR has been the topic of a number of recent research reports. BTIG Research boosted their price objective on LENSAR from $7.00 to $9.00 and gave the stock a “buy” rating in a research note on Thursday, August 13th. Wall Street Zen raised LENSAR from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Lake Street Capital reissued a “buy” rating and set a $13.00 price target on shares of LENSAR in a research report on Thursday, August 13th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of LENSAR in a report on Friday, August 7th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $11.00.

LENSAR Stock Up 6.5%

LNSR stock opened at $8.72 on Thursday. LENSAR, Inc. has a 52-week low of $4.95 and a 52-week high of $12.96. The stock has a market cap of $107.17 million, a price-to-earnings ratio of -26.42 and a beta of 0.89. The business has a fifty day moving average of $6.05 and a two-hundred day moving average of $7.25.

LENSAR (NASDAQ:LNSR) last announced its quarterly earnings results on Thursday, August 13th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.16) by $0.26. The business had revenue of $16.50 million for the quarter, compared to analyst estimates of $14.65 million. LENSAR had a negative return on equity of 529.08% and a net margin of 57.57%.

LENSAR Company Profile

LENSAR, Inc, headquartered in Orlando, Florida, is a medical technology company specializing in advanced laser systems for ophthalmic surgery. Its flagship product, the LENSAR Laser System, combines proprietary three-dimensional imaging with precision-guided femtosecond laser delivery to perform critical steps in cataract procedures, including capsulotomy creation, lens fragmentation and corneal incisions.

Founded in 2005, LENSAR has concentrated its research and development efforts on enhancing surgical accuracy and patient outcomes in cataract treatment.